Locations:
October 14, 2019/Cancer/News & Insight

Jame Abraham, MD, FACP, Named Chair of Hematology/Medical Oncology

Renowned breast cancer researcher and editor to lead department

650×450-Jame-Abraham

Jame Abraham, MD, FACP, is the new Chair of Hematology/Medical Oncology at Cleveland Clinic.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

In his new position, Dr. Abraham will recruit and develop staff, and guide the department’s focus on patient access and multidisciplinary care. He also will continue as Professor of Medicine at Cleveland Clinic Lerner College of Medicine.

Most recently, Dr. Abraham was Director of the Breast Oncology Program at Cleveland Clinic’s Taussig Cancer Institute and Co-Director of the Cleveland Clinic Comprehensive Breast Cancer Program.

“Successfully leading our Hematology/Medical Oncology Department requires a leader who excels at empathy, fosters a culture of teamwork, demonstrates emotional intelligence and believes in the vision of our institute,” says Brian Bolwell, MD, Chairman, Taussig Cancer Institute, Cleveland Clinic Cancer Center. “Dr. Abraham represents these qualities and has exhibited a passion for department and caregiver development, and elevating our national reputation.”

About Dr. Abraham

Dr. Abraham earned his medical degree from Calicut Medical College in Kerala, India. He then completed a residency at the University of Connecticut, followed by a fellowship in hematology at the National Heart, Lung, and Blood Institute and a fellowship in medical oncology at the National Cancer Institute.

He worked as Chief of Hematology/Oncology, Professor of Medicine and Bonnie Wells Wilson Distinguished Professor of Breast Cancer Research at West Virginia University before joining Cleveland Clinic in 2013.

A national principal investigator of multiple breast cancer clinical trials, Dr. Abraham has published and presented more than 200 papers. He also is Founding Editor of The Bethesda Handbook of Clinical Oncology.

Advertisement

His national breast cancer committee and leadership activities include serving as:

  • Member of the National Comprehensive Cancer Network (NCCN) Breast Cancer Committee.
  • Vice Chair of NRG Oncology’s Research Strategy Committee.
  • Member of NRG Oncology’s Breast Cancer Working Committee.
  • Vice Chair of the National Surgical Adjuvant Breast and Bowel Project (NSABP) Research Review Committee.

“I look forward to building upon Cleveland Clinic Taussig Cancer Institute’s position as a leader in hematology and medical oncology, delivering outstanding, compassionate patient care and innovative research,” says Dr. Abraham. “I am honored to serve patients who choose Cleveland Clinic for advanced cancer treatment and to support the department’s committed and passionate caregivers.”

Advertisement

Related Articles

Dr. Arun Singh
October 21, 2026/Cancer

Preserving Vision in Uveal Melanoma (Podcast)

Understanding expanding treatment options and potential advances

Patient and doctor
October 9, 2026/Cancer/News & Insight

First Radioligand Therapy Approved for Metastatic Hormone-Sensitive Prostate Cancer

Adding 177Lu-PSMA-617 to ADT plus an ARPI cut the risk of radiographic progression or mortality by 28%

Woman running
October 7, 2026/Cancer/Patient Support

Pilot Project Aids Cancer Survivors in Achieving Healthy Weight and Reducing Recurrent Risk

New program will help patients improve fitness and manage weight after cancer treatment

Dr Keith McCrae
October 6, 2026/Cancer/Benign Hematology

How is ITP Therapy Evolving?

Cleveland Clinic hematologist highlights new guidelines and treatment advances in immune thrombocytopenia

Bone metastasis
October 5, 2026/Cancer/Innovations

Digital Platform Cuts Bone Metastasis Treatment Decision Time

NIMBLE replaces weekly tumor board delays with same-day multidisciplinary recommendations

Prostate cancer
October 2, 2026/Cancer/Radiation Oncology

ArteraAI Prostate Biomarker Accurate Across Diverse Populations

Cleveland Clinic study provides validation for the test, which combines AI and pathological data to predict outcomes in postoperative patients

Prostate cancer illustration
October 1, 2026/Cancer/Radiation Oncology

PSMA PET Scan-Guided LDR Brachytherapy Can Control Localized Prostate Cancer Recurrence

Advanced imaging technology catches metastases much earlier, allowing treatment with fewer side effects

Throat cancer
September 30, 2026/Cancer/Radiation Oncology

Same Cure Rate, Less Radiation in HPV-Associated Oral Cancer

Reduced radiation for lymph node areas reduces side effects

Ad